Insider Selling: Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells $455,496.68 in Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek J. Maetzold sold 22,639 shares of the stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $20.12, for a total value of $455,496.68. Following the sale, the insider now owns 80,465 shares in the company, valued at $1,618,955.80. The trade was a 21.96 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Castle Biosciences Stock Down 4.4 %

CSTL opened at $18.76 on Friday. Castle Biosciences, Inc. has a 12 month low of $16.97 and a 12 month high of $35.84. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.78 and a quick ratio of 7.64. The stock has a market cap of $525.41 million, a P/E ratio of 93.80 and a beta of 0.98. The stock’s 50 day moving average price is $25.99 and its 200 day moving average price is $28.70.

Analyst Ratings Changes

CSTL has been the topic of a number of research reports. Robert W. Baird increased their price target on Castle Biosciences from $36.00 to $37.00 and gave the stock an “outperform” rating in a research report on Friday, February 28th. Stephens reiterated an “overweight” rating and set a $41.00 price target on shares of Castle Biosciences in a research report on Thursday, January 2nd. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, Castle Biosciences presently has a consensus rating of “Buy” and a consensus price target of $40.00.

Institutional Trading of Castle Biosciences

Several large investors have recently added to or reduced their stakes in CSTL. US Bancorp DE boosted its stake in Castle Biosciences by 1,889.2% during the 3rd quarter. US Bancorp DE now owns 4,615 shares of the company’s stock valued at $132,000 after purchasing an additional 4,383 shares in the last quarter. Principal Financial Group Inc. boosted its stake in Castle Biosciences by 2.7% during the 3rd quarter. Principal Financial Group Inc. now owns 1,538,520 shares of the company’s stock valued at $43,879,000 after purchasing an additional 40,377 shares in the last quarter. Assetmark Inc. boosted its stake in Castle Biosciences by 16.8% during the 3rd quarter. Assetmark Inc. now owns 5,212 shares of the company’s stock valued at $149,000 after purchasing an additional 748 shares in the last quarter. Lisanti Capital Growth LLC boosted its stake in Castle Biosciences by 60.2% during the 3rd quarter. Lisanti Capital Growth LLC now owns 154,710 shares of the company’s stock valued at $4,412,000 after purchasing an additional 58,160 shares in the last quarter. Finally, GSA Capital Partners LLP bought a new position in Castle Biosciences during the 3rd quarter valued at $1,478,000. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.